Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB-DYYB Cause Therapeutic product effect delayed? 45 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 45 reports of Therapeutic product effect delayed have been filed in association with INFLIXIMAB-DYYB (ZYMFENTRA). This represents 0.2% of all adverse event reports for INFLIXIMAB-DYYB.

45
Reports of Therapeutic product effect delayed with INFLIXIMAB-DYYB
0.2%
of all INFLIXIMAB-DYYB reports
2
Deaths
19
Hospitalizations

How Dangerous Is Therapeutic product effect delayed From INFLIXIMAB-DYYB?

Of the 45 reports, 2 (4.4%) resulted in death, 19 (42.2%) required hospitalization.

Is Therapeutic product effect delayed Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB-DYYB. However, 45 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB-DYYB Cause?

Off label use (14,256) Condition aggravated (10,275) Intentional product use issue (7,549) Inappropriate schedule of product administration (5,977) Arthralgia (4,615) Drug ineffective (3,112) Fatigue (3,111) Weight increased (2,848) Malaise (2,766) Weight decreased (2,703)

What Other Drugs Cause Therapeutic product effect delayed?

ADALIMUMAB (244) TOFACITINIB (178) CARBIDOPA\LEVODOPA (168) SECUKINUMAB (162) POLYETHYLENE GLYCOL 3350 (125) RIMEGEPANT (120) TASIMELTEON (93) DUPILUMAB (90) IBUPROFEN (88) DICLOFENAC (85)

Which INFLIXIMAB-DYYB Alternatives Have Lower Therapeutic product effect delayed Risk?

INFLIXIMAB-DYYB vs INFLIXIMAB-QBTX INFLIXIMAB-DYYB vs INFLIXIMAB, RECOMBINANT INFLIXIMAB-DYYB vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE INFLIXIMAB-DYYB vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B

Related Pages

INFLIXIMAB-DYYB Full Profile All Therapeutic product effect delayed Reports All Drugs Causing Therapeutic product effect delayed INFLIXIMAB-DYYB Demographics